QuidelOrtho's Earnings Tuesday: What the Respiratory Season Didn't Deliver

QuidelOrtho Corp (QDEL) reports first-quarter 2026 earnings tomorrow, May 5th, after market close, with analysts expecting a sharp year-over-year decline in profitability. The central question is whether the diagnostics company can stabilize its business after a volatile 2025 that saw dramatic earnings swings and mounting pressure on its core testing segments. With the stock down nearly 50% over the past year and trading well below all major moving averages, investors will scrutinize management's guidance and commentary for signs of a sustainable turnaround.

Part 1: Earnings Preview

QuidelOrtho Corp develops, manufactures, and markets diagnostic testing solutions for healthcare providers, with a portfolio spanning immunoassays, molecular diagnostics, and point-of-care testing products. The company serves hospitals, laboratories, and physician offices globally, with particular strength in infectious disease and women's health diagnostics.

QDEL reports Q1 2026 earnings tomorrow after market close, with the consensus estimate calling for $0.37 per share—a steep 50% decline from the $0.74 reported in Q1 2025. Most recently, the company posted $0.46 per share in Q4 2025, beating the $0.43 estimate by 7%. The year-over-year comparison underscores the challenge: analysts expect first-quarter earnings to fall by half as the company cycles difficult comparisons and navigates ongoing headwinds.

Three key themes define this earnings story:

Post-pandemic normalization pressures: QuidelOrtho continues to face declining demand for COVID-19 testing products that drove outsized results in prior years. Investors will watch whether the company's base diagnostics business—respiratory panels, cardiac markers, and women's health tests—can offset the revenue gap left by fading pandemic tailwinds. Management's commentary on underlying organic growth rates will be critical.

Margin compression and cost structure: The sharp earnings decline reflects not just revenue pressure but also margin headwinds as the company absorbs fixed costs across a smaller revenue base. Analysts are focused on whether QuidelOrtho can execute operational efficiencies and rationalize its cost structure without sacrificing R&D investments needed for future growth. Any guidance on gross margin trends and operating leverage will move the stock.

Capital allocation and balance sheet management: With $2.84 billion in debt against $169.8 million in cash, QuidelOrtho's leverage profile remains a concern. Investors want clarity on free cash flow generation, debt reduction plans, and whether the company has flexibility to invest in growth initiatives or pursue strategic M&A. Management's capital allocation priorities will signal confidence in the business trajectory.

Analyst commentary ahead of the release reflects caution. The consensus has deteriorated over the past month, with one analyst downgrading from Moderate Buy to Hold. Price targets range from $15 to $38, with a mean of $27—implying 117% upside from current levels but also highlighting the wide dispersion in views. The bearish camp points to structural headwinds in the diagnostics market and execution risks, while bulls argue the stock has overshot to the downside and see value in the company's installed base and product pipeline.

Part 2: Historical Earnings Performance

QuidelOrtho has delivered a mixed but generally positive earnings track record over the past four quarters, beating estimates in three of four reports. The company posted its largest surprise in Q3 2025, reporting $0.80 against a $0.51 estimate—a 57% beat that demonstrated stronger-than-expected demand for core diagnostics products. Q1 2025 also delivered a solid 30% beat with $0.74 versus $0.57 expected, while the most recent Q4 2025 result came in at $0.46, modestly ahead of the $0.43 consensus.

The Q2 2025 report stands out as an anomaly: the company posted $0.12 against a $0.00 estimate, making the percentage surprise calculation meaningless but reflecting a return to profitability when analysts had expected breakeven. This pattern suggests QuidelOrtho has consistently managed to outperform lowered expectations, though the absolute earnings levels have trended downward from the $0.74 peak in Q1 2025 to $0.46 in Q4 2025.

The trend reveals a company navigating a difficult transition but retaining the ability to surprise positively. However, the magnitude of beats has narrowed—from 30% and 57% in the first half of 2025 to just 7% in Q4—suggesting either that management guidance has become more accurate or that the company's ability to exceed expectations is diminishing as easier comparisons fade.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

QuidelOrtho typically reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual numbers.

The historical data reveals extreme volatility in post-earnings price action, with Day +1 moves averaging 13.50% in absolute terms and ranging as high as 41% (May 2025, when the stock surged following a beat). The most recent report in February 2026 triggered a 17.59% decline the following day despite a modest earnings beat, suggesting investors were disappointed by guidance or underlying business trends. November 2025 saw an even sharper 22.32% drop after a massive 57% earnings beat, indicating that strong results alone haven't been enough to sustain rallies.

The pattern shows Day 0 moves are relatively muted (averaging 1.86%), but Day +1 reactions are violent and unpredictable—ranging from a 22% decline to a 41% gain. The Day +1 range averages 15.84%, meaning the stock typically swings across a 16-percentage-point band in the session following results. This volatility reflects deep uncertainty about QuidelOrtho's business trajectory and suggests the market is hypersensitive to guidance, margin commentary, and management's tone. Investors should brace for significant price movement regardless of whether the company beats or misses the $0.37 estimate.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.78% expected move through the May 15th expiration, implying a range of $10.58 to $14.26. This sits slightly above the 13.50% average Day +1 move but well below the 15.84% average Day +1 range, suggesting options traders are anticipating elevated but not extreme volatility. However, given that two of the last eight earnings reports triggered Day +1 moves exceeding 20%, the options market may be underpricing tail risk.

Part 3: What Analysts Are Saying

Analysts remain deeply divided on QuidelOrtho, with the current consensus rating at 3.00 (Hold) and a mean price target of $27—implying 117% upside from the current $12.42 price. The breakdown shows 2 Strong Buys, 0 Moderate Buys, 3 Holds, 0 Moderate Sells, and 2 Strong Sells, reflecting a polarized view where bulls and bears are equally represented with little middle ground.

Sentiment has deteriorated over the past month, with one analyst downgrading from Moderate Buy to Hold, pushing the average recommendation from 3.13 to 3.00. This shift reflects growing caution as the Q1 estimate has been revised downward and concerns about the company's ability to stabilize earnings have intensified. The wide dispersion in price targets—ranging from a low of $15 to a high of $38—underscores the uncertainty, with bears seeing limited upside and bulls arguing the stock has been oversold.

The $27 consensus target implies substantial upside, but investors should note that the stock has consistently traded below analyst expectations over the past year, suggesting either that targets are stale or that the market is pricing in execution risks and structural headwinds that analysts have been slow to fully incorporate. The Hold rating and deteriorating sentiment suggest analysts are adopting a wait-and-see posture heading into tomorrow's report.

Part 4: Technical Picture

QuidelOrtho enters earnings in a deeply oversold technical position, with the Barchart Technical Opinion registering a 100% Sell signal—unchanged from last week but strengthened from 88% Sell a month ago. The signal has been consistently bearish, and the recent strengthening to maximum bearish intensity reflects accelerating downside momentum as the stock has broken below key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Maximum sell signal indicates severe near-term downside pressure with no technical support in sight
• Medium-term (100% Sell): Bearish reading across the intermediate timeframe confirms the downtrend is entrenched, not just a short-term dip
• Long-term (100% Sell): Maximum long-term sell signal reflects a broken chart structure with all major moving averages in bearish alignment

Trend Characteristics: The Maximum Strengthening trend environment heading into earnings signals that selling pressure is intensifying rather than stabilizing, creating a hostile technical backdrop where any disappointment could trigger further liquidation.

The stock is trading at $12.42, below all major moving averages: above the 5-day ($12.17) and 10-day ($11.99) but below the 20-day ($13.37), 50-day ($16.50), 100-day ($22.78), and 200-day ($24.72). The fact that QDEL sits 50% below its 200-day moving average illustrates the severity of the downtrend. The 20-day average at $13.37 represents immediate resistance, while the 50-day at $16.50 would require a massive post-earnings rally to reclaim.

The technical setup is unambiguously bearish heading into earnings, with no meaningful support levels nearby and all longer-term moving averages in steep decline. The stock's position below the 20-day, 50-day, 100-day, and 200-day averages signals that the path of least resistance remains lower unless management delivers a transformational beat and raises guidance substantially. The maximum sell signal and strengthening downtrend suggest the market is positioned for disappointment, meaning even an in-line result could trigger further selling. Only a significant positive surprise accompanied by credible guidance for margin recovery and revenue stabilization would likely reverse the technical damage. Investors should approach with caution, as the chart offers no cushion for any misstep.